Matrix Partners China

Founded 1977
Founders Bo Shao David Su David Zhang Yee Lee


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 503
Average round size
The average size of a deal this fund participated in
Portfolio companies 382
Rounds per year 11.43
Lead investments 119
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 34
Key employees 11
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Health Care
  • Internet
  • Software
  • E-Commerce
  • Information Technology

Matrix Partners China appeared to be the VC, which was created in 1977. The company was established in Asia in China. The main department of described VC is located in the Beijing.

Considering the real fund results, this VC is 10 percentage points more often commits exit comparing to other organizations. This Matrix Partners China works on 22 percentage points less the average amount of lead investments comparing to the other organizations. When the investment is from Matrix Partners China the average startup value is more than 1 billion dollars. The fund is constantly included in 25-48 investment rounds annually. The top amount of exits for fund were in 2018. The common things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity.

The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Matrix Partners China, startups are often financed by Matrix Partners, Eastern Bell Venture Capital, Tencent Holdings. The meaningful sponsors for the fund in investment in the same round are Vision Plus Capital, Tencent Holdings, DCM Ventures. In the next rounds fund is usually obtained by GGV Capital, DST Global, K2VC.

The fund has specific favorite in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Among the most successful fund investment fields, there are Mobile, Internet. Among the various public portfolio startups of the fund, we may underline, Guazi (Chehaoduo), Lianjia (Homelink)

The current fund was established by Yee Lee. Besides them, we counted 11 critical employees of this fund in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Matrix Partners China:
Typical Co-investors
Matrix Partners China is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Matrix Partners China:

Funds with similar focus

Funds from China, Beijing
Funds with similar focus located in China, Beijing:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Space Transportation

Industrial Design
Industrial Engineering
Industrial Manufacturing
Space Travel
$46M09 Aug 2021 China, Dongcheng District


$61M03 Aug 2021 China, Shanghai


$154M26 Jul 2021 China, Xuanwu District

PAQ Therapeutics

Health Care
$30M15 Jul 2021 United States, Cambridge

GRIT Biotechnology

Health Care
Medical Device
14 Jul 2021 China, Shanghai

Shanghai LinkedCare Information Technology

Health Care
$100M23 Jun 2021 China, Shanghai

Nutshell Therapeutics

Health Care
Product Research
$20M15 Jun 2021 China, Huangpu


Health Care
Medical Device
Product Research
$10M11 Jun 2021 China Minhang District


Artificial Intelligence
$65M28 May 2021 Beijing China Dongcheng District
Scivita Medical Technology Receives RMB0.4 Billion in Series B Financing

– Scivita Medical Technology Co., Ltd. from Hong Kong is a maker of endoscopy products.
– The company received nearly RMB0.4 Billion in Series B financing.
– Backers included new investors such as Hudson Bay Capital Management and Prime Capital, as well as existing shareholders such as GL Ventures, Lilly Asia Ventures and Matrix Partners China.
– The new investment will be used for research and development, capacity expansion, and domestic and international commercialization of innovative products in endoscopy and related fields.

Bota Bio Raises $100 Million Series B Financing to Advance Sustainable Biomanufacturing

– Bota Bio has raised more than $100m in an oversubscribed Series B funding round.
– The financing was led by Sequoia Capital China.
– Other investors included previous backers Matrix Partners China, Source Code Capital, Sherpa Healthcare Partners, and 5Y Capital, among others.
– The new funds will be used to expand the company’s global operations and build out Bota Bio’s lab-to-pilot scale platform to facilitate the rapid scale-up and deployment of the company’s product pipeline in consumer goods, food, nutrition, and pharmaceutical products.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Matrix Partners China?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: